Summary
In low-risk patients with troponin-negative acute coronary syndromes undergoing ad hoc percutaneous coronary intervention, ticagrelor treatment resulted in greater reductions of platelet reactivity and a greater increase in inhibition of platelet aggregation compared with clopidogrel.
- ACS
- acute coronary syndromes
- ticagrelor
- clopidogrel
- platelet reactivity
- cardiology & cardiovascular medicine clinical trials
- interventional techniques & devices
- thrombotic disorders
- © 2015 SAGE Publications
Tools
Ticagrelor Reduces Platelet Reactivity in Troponin Negative Patients With ACS Undergoing Non-Urgent PCI
Permalink:
Table of contents
Cited By...
- No citing articles found.